The enhanced anti-tumor effect of α-CD137/α-PD-1 mAbs when combined with radiotherapy was associated with accumulation (>60-fold) of intratumoral CD4+ and CD8+ T cells with an effector phenotype, which contributed to the therapeutic effect of this radio-immunotherapy approach. This evidence concerns the gene TNFRSF9 and neoplasm.